Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Potent and selective PTDSS1 inhibitor targeting collateral lethality against cancer with PTDSS2 deletion [cell_RNA-seq]

ABSTRACT: To decipher the underlying mechanism governing selective growth arrest in PTDSS1-inhibited PTDSS2-depleted cancer cells, we analyzed the transcriptomic changes brought about by comparing DMSO treated and DS07551382 treated wild type or PTDSS2-depleted cells.

ORGANISM(S): Homo sapiens

PROVIDER: GSE206516 | GEO | 2022/08/31

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Potent and selective PTDSS1 inhibitor targeting collateral lethality against cancer with PTDSS2 deletion [xeno_RNA-seq]

Project description:To decipher the underlying mechanism governing selective growth arrest in PTDSS1-inhibited PTDSS2-depleted cancer cells, we analyzed the transcriptomic changes brought about by comparing vehecle treated and DS55980254 treated PTDSS2-KO HCT116 s.c. tumors.

2022-08-31 | GSE206517 | GEO

Potent and selective PTDSS1 inhibitor targeting collateral lethality against cancer with PTDSS2 deletion

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-08-31 | GSE206518 | GEO

Genomic deletion of malic enzyme 2 confers collateral lethality in pancreas cancer

Project description:Comparison of malic enzyme 3 (ME3) depleted vs non-depleted xenograft tumors. ME3 is an isoform of ME2.

2017-08-22 | GSE80411 | GEO

CPI-0610, a potent and selective BET bromodomain inhibitor optimized for clinical development

Project description:SUDHL5 cells were treated with DMSO or 2.5 μM CPI203 for 4 hours, then processed for ChIP-Seq to obtain genome-wide binding changes for BRD4 upon treatment with a BET inhibitor.

2023-01-06 | GSE71758 | GEO

Potent and selective PTDSS1 inhibitor targeting collateral lethality against cancer with PTDSS2 deletion

Project description:Potent and selective PTDSS1 inhibitor targeting collateral lethality against cancer with PTDSS2 deletion

| PRJNA851246 | ENA

Potent and selective PTDSS1 inhibitor targeting collateral lethality against cancer with PTDSS2 deletion [xeno_RNA-seq]

Project description:Potent and selective PTDSS1 inhibitor targeting collateral lethality against cancer with PTDSS2 deletion [xeno_RNA-seq]

| PRJNA851250 | ENA

Potent and selective PTDSS1 inhibitor targeting collateral lethality against cancer with PTDSS2 deletion [cell_RNA-seq]

Project description:Potent and selective PTDSS1 inhibitor targeting collateral lethality against cancer with PTDSS2 deletion [cell_RNA-seq]

| PRJNA851252 | ENA

Study of Potent inhibitors for CT5-3hTERT fibroblast cell line

Project description:Data independent acquisition (DIA) mass spectrometry was used to study the potent inhibitors for cancer derived fibroblast cell line, CT5-3hTERT. The fibroblast spheroids were treated with 21 different tumor inhibitors to compare their effect in proteome in comparison to treated with DMSO.

2024-08-10 | PXD050005 | Pride

Amorfrutins are selective PPARM-NM-3 agonists with potent antidiabetic properties

Project description:Faced by an alarming incidence of metabolic diseases including obesity and type 2 diabetes worldwide, there is an urgent need for effective strategies for preventing and treating these common diseases. The nuclear receptor PPARM-NM-3 (peroxisome proliferator-activated receptor gamma) plays a crucial role in metabolism. We isolated the amorfrutins from edible parts of the plants Glychyrrhiza foetida and Amorpha fruticosa, and identified these natural products as a new chemical class to treat insulin resistance and diabetes by selectively activating PPARM-NM-3. In contrast to existing synthetic PPARM-NM-3 drugs, the amorfrutins display unique properties by separating insulin sensitization from unwanted side effects. In obese mouse models, amorfrutin treatment significantly improved important metabolic and inflammatory parameters. In summary, PPARM-NM-3 activation by selective amorfrutins derived from edible biomaterial is a promising approach to combat metabolic diseases and other diseases in which PPARM-NM-3 is involved in. GSM701612-GSM701623: Male DIO C57BL/6 mice (age 18 wks), 3 groups (n=4 each after pooling of 8 samples per group). Mice were fed over 3 wks with high fat diet (HFD) without compound (vehicle), HFD with 4 mg/kg/d rosiglitazone or with 100 mg/kg/d amorfrutin 1. Liver RNA extracted. --> 4 biological replicates, vehicle vs. rosiglitazone or amorfrutin 1 GSM702299-GSM702344: Biological replicates (n = 3-4 each) of human primary adipocytes were treated with the following compounds for 24 hours. 10M-BM-5M rosiglitazone, 10M-BM-5M pioglitazone, 30M-BM-5M telmisartan, 10M-BM-5M nTZDpa, 30M-BM-5M amorfrutin 1, 30M-BM-5M amorfrutin 2, 30M-BM-5M amorfrutin 3 or 30M-BM-5M amorfrutin 4 vs. 0.1% DMSO (vehicle)

2012-05-01 | E-GEOD-28384 | biostudies-arrayexpress

Selective inhibition of CDK7 reveals the influence of CDK7 on psoriatic CD4+ T cells

Project description:Purpose: The goals of this study are to compare the differential gene of psoriatic CD4+ T cells treated with THZ1 and DMSO Methods: RNA sequencing of psoriatic CD4+ T cells which treated with THZ1 (10 nM) or DMSO

2021-04-09 | GSE171676 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data